valproic acid has been researched along with Angiogenesis, Pathologic in 20 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the present study was to investigate the effects of sodium valproate (VPA), a histone deacetylase inhibitor, in combination with hydralazine hydrochloride (Hy), a DNA methylation inhibitor, on the expression of VEGI and its related receptors in human osteosarcoma (OS) cell lines and human microvascular endothelial (HMVE) cells." | 7.91 | Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells. ( Fujihara, Y; Futani, H; Kobayashi, K; Kumanishi, S; Nakasho, K; Nishiura, H; Yamanegi, K; Yoshiya, S, 2019) |
| "To develop novel orthotopic xenograft models of medulloblastoma in severe combined immunodeficient mice and to evaluate the in vivo antitumor efficacy of valproic acid." | 7.73 | Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts. ( Adesina, A; Antalffy, B; Blaney, SM; Lau, CC; Li, XN; Ou, CN; Pietsch, T; Shu, Q; Su, JM, 2006) |
| " Our results indicate that ABT-510 combined with VPA may be an effective antiangiogenic treatment strategy for children with high-risk neuroblastoma." | 5.34 | Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. ( Chlenski, A; Cohn, SL; Henkin, J; Liu, S; Salwen, HR; Tian, Y; Yang, Q; Zeine, R, 2007) |
| " The aim of the present study was to investigate the effects of sodium valproate (VPA), a histone deacetylase inhibitor, in combination with hydralazine hydrochloride (Hy), a DNA methylation inhibitor, on the expression of VEGI and its related receptors in human osteosarcoma (OS) cell lines and human microvascular endothelial (HMVE) cells." | 3.91 | Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells. ( Fujihara, Y; Futani, H; Kobayashi, K; Kumanishi, S; Nakasho, K; Nishiura, H; Yamanegi, K; Yoshiya, S, 2019) |
| "To develop novel orthotopic xenograft models of medulloblastoma in severe combined immunodeficient mice and to evaluate the in vivo antitumor efficacy of valproic acid." | 3.73 | Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts. ( Adesina, A; Antalffy, B; Blaney, SM; Lau, CC; Li, XN; Ou, CN; Pietsch, T; Shu, Q; Su, JM, 2006) |
| "Cervical cancer is one of the most prevalent malignancies in women worldwide." | 1.43 | Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1α/VEGF signals. ( Chi, Y; Du, R; Tang, W; You, W; Zhao, Y; Zheng, J, 2016) |
| "Only a minority of men succumb to prostate cancer (PCa)." | 1.43 | Valproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models. ( Bratslavsky, G; Byler, T; Caza, T; Chelluri, R; Reeder, JE; Woodford, MR, 2016) |
| "Valproic acid (VPA) is a potent anticancer and antiangiogenic agent." | 1.40 | Biological screening of novel derivatives of valproic acid for anticancer and antiangiogenic properties. ( Baabbad, A; El-Faham, A; Elkayal, AM; Farooq, M; Hamed, EA; Ibrahim, MF; Khattab, SN; Taha, NA; Wadaan, MA, 2014) |
| "A human ovarian cancer model transplanted subcutaneously in nude mice was established, and the efficacy of VPA used alone and in combination with diammine dichloroplatinum (DDP) to inhibit the growth of tumors was also assessed." | 1.38 | Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo. ( Feng-Nian, R; Jie, G; Shan, Z; Ting, Z, 2012) |
| " Chronic administration of VPA had a net cytostatic effect that resulted in a statistically significant reduction of tumour growth and improved survival advantages in tumour xenografts studies." | 1.35 | Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. ( Höti, N; Huang, X; Sami, S; Shen, Z; Xu, HM, 2008) |
| " Our results indicate that ABT-510 combined with VPA may be an effective antiangiogenic treatment strategy for children with high-risk neuroblastoma." | 1.34 | Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. ( Chlenski, A; Cohn, SL; Henkin, J; Liu, S; Salwen, HR; Tian, Y; Yang, Q; Zeine, R, 2007) |
| "Valproic acid (VPA), is a drug approved by the FDA for epilepsy and bipolar disorders." | 1.34 | Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. ( Carducci, MA; Galloway, N; Kachhap, S; Kortenhorst, MS; Rodriguez, R; Shabbeer, S, 2007) |
| " However, due to its poor bioavailability in vivo, the therapeutic use of butyrate is limited." | 1.32 | Modulation of angiogenesis-related protein synthesis by valproic acid. ( Becker, U; Loitsch, S; Stein, J; Zgouras, D, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 13 (65.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sawai, T | 1 |
| Yamanegi, K | 2 |
| Nishiura, H | 2 |
| Futani, H | 2 |
| Tachibana, T | 1 |
| Valiulytė, I | 1 |
| Curkūnavičiūtė, R | 1 |
| Ribokaitė, L | 1 |
| Kazlauskas, A | 1 |
| Vaitkevičiūtė, M | 1 |
| Skauminas, K | 1 |
| Valančiūtė, A | 1 |
| Iizuka, N | 1 |
| Morita, A | 1 |
| Kawano, C | 1 |
| Mori, A | 1 |
| Sakamoto, K | 1 |
| Kuroyama, M | 1 |
| Ishii, K | 1 |
| Nakahara, T | 1 |
| Wu, H | 1 |
| Ding, J | 1 |
| Wang, L | 1 |
| Lin, J | 1 |
| Li, S | 1 |
| Xiang, G | 1 |
| Jiang, L | 1 |
| Xu, H | 1 |
| Gao, W | 1 |
| Zhou, K | 1 |
| Kumanishi, S | 1 |
| Fujihara, Y | 1 |
| Kobayashi, K | 1 |
| Nakasho, K | 1 |
| Yoshiya, S | 1 |
| Wang, LH | 2 |
| Zhang, ZH | 2 |
| Zhao, L | 2 |
| Zhu, CM | 2 |
| Zhao, LS | 1 |
| Hao, CL | 2 |
| Liu, P | 1 |
| Tian, X | 1 |
| Hsieh, CL | 1 |
| Chen, KC | 1 |
| Ding, CY | 1 |
| Tsai, WJ | 1 |
| Wu, JF | 1 |
| Peng, CC | 1 |
| Farooq, M | 1 |
| El-Faham, A | 1 |
| Khattab, SN | 1 |
| Elkayal, AM | 1 |
| Ibrahim, MF | 1 |
| Taha, NA | 1 |
| Baabbad, A | 1 |
| Wadaan, MA | 1 |
| Hamed, EA | 1 |
| Zhao, Y | 1 |
| You, W | 1 |
| Zheng, J | 1 |
| Chi, Y | 1 |
| Tang, W | 1 |
| Du, R | 1 |
| Chelluri, R | 1 |
| Caza, T | 1 |
| Woodford, MR | 1 |
| Reeder, JE | 1 |
| Bratslavsky, G | 1 |
| Byler, T | 1 |
| Sami, S | 1 |
| Höti, N | 1 |
| Xu, HM | 1 |
| Shen, Z | 1 |
| Huang, X | 1 |
| Osuka, S | 1 |
| Takano, S | 1 |
| Watanabe, S | 1 |
| Ishikawa, E | 1 |
| Yamamoto, T | 1 |
| Matsumura, A | 1 |
| Sidana, A | 1 |
| Wang, M | 1 |
| Shabbeer, S | 2 |
| Chowdhury, WH | 1 |
| Netto, G | 1 |
| Lupold, SE | 1 |
| Carducci, M | 1 |
| Rodriguez, R | 2 |
| Shan, Z | 1 |
| Feng-Nian, R | 1 |
| Jie, G | 1 |
| Ting, Z | 1 |
| Zgouras, D | 1 |
| Becker, U | 1 |
| Loitsch, S | 1 |
| Stein, J | 1 |
| Shu, Q | 1 |
| Antalffy, B | 1 |
| Su, JM | 1 |
| Adesina, A | 1 |
| Ou, CN | 1 |
| Pietsch, T | 1 |
| Blaney, SM | 1 |
| Lau, CC | 1 |
| Li, XN | 1 |
| Yang, Q | 1 |
| Tian, Y | 1 |
| Liu, S | 1 |
| Zeine, R | 1 |
| Chlenski, A | 1 |
| Salwen, HR | 1 |
| Henkin, J | 1 |
| Cohn, SL | 1 |
| Kortenhorst, MS | 1 |
| Kachhap, S | 1 |
| Galloway, N | 1 |
| Carducci, MA | 1 |
| Gao, D | 1 |
| Xia, Q | 1 |
| Lv, J | 1 |
| Zhang, H | 1 |
20 other studies available for valproic acid and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Sodium Valproate Enhances Semaphorin 3A-mediated Anti-angiogenesis and Tumor Growth Inhibition in Human Osteosarcoma Cells.
Topics: Bone Neoplasms; Histone Deacetylase Inhibitors; Humans; Neovascularization, Pathologic; Neuropilin-1 | 2023 |
The Anti-Tumorigenic Activity of Sema3C in the Chick Embryo Chorioallantoic Membrane Model.
Topics: Animals; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Glioblastoma; Humans; Neoplasm In | 2019 |
Anti-angiogenic effects of valproic acid in a mouse model of oxygen-induced retinopathy.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Mice; Neovascularization, Pathologic; Oxyg | 2018 |
Valproic acid enhances the viability of random pattern skin flaps: involvement of enhancing angiogenesis and inhibiting oxidative stress and apoptosis.
Topics: Animals; Apoptosis; Injections, Intraperitoneal; Male; Neovascularization, Pathologic; Oxidative Str | 2018 |
Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells.
Topics: Bone Neoplasms; Cell Line; Cell Line, Tumor; Drug Synergism; Endothelial Cells; Enzyme Inhibitors; E | 2019 |
[Effect of valproic acid against angiogenesis of Kasumi-1 xenograft tumor in nude mice].
Topics: Angiopoietins; Animals; Antigens, CD34; Cell Line, Tumor; Female; Humans; Leukemia, Myeloid, Acute; | 2013 |
Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi‑1 leukemia cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fibroblast Growth Factor 2; Gene Expressio | 2014 |
Valproic acid substantially downregulated genes folr1, IGF2R, RGS2, COL6A3, EDNRB, KLF6, and pax-3, N-acetylcysteine alleviated most of the induced gene alterations in chicken embryo model.
Topics: Acetylcysteine; Animals; Avian Proteins; Chick Embryo; Chromatography, High Pressure Liquid; Collage | 2013 |
Biological screening of novel derivatives of valproic acid for anticancer and antiangiogenic properties.
Topics: Angiogenesis Inhibitors; Animals; Animals, Genetically Modified; Anticonvulsants; Carcinoma, Hepatoc | 2014 |
Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1α/VEGF signals.
Topics: Angiogenesis Inhibitors; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immu | 2016 |
Valproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Neovascu | 2016 |
Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; | 2008 |
Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain.
Topics: Angiogenesis Inhibitors; Animals; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Cell Line | 2012 |
Mechanism of growth inhibition of prostate cancer xenografts by valproic acid.
Topics: Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitor | 2012 |
Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo.
Topics: Animals; Anticonvulsants; Apoptosis; Blotting, Western; Cell Adhesion; Cell Cycle; Cell Movement; Ce | 2012 |
Modulation of angiogenesis-related protein synthesis by valproic acid.
Topics: Blotting, Western; Butyrates; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Cysteine Endopeptid | 2004 |
Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts.
Topics: Animals; Carcinogenicity Tests; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2006 |
Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capilla | 2007 |
Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senesc | 2007 |
Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
Topics: Acetylation; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhib | 2007 |